In a large and heavily networked specialty like gynaecology it is a particular challenge with regard to future status to achieve excellent patient care, research and teaching. At the same time not only hospitals but also research facilities are experiencing increasing pressure from performance and competition sides in terms of survival and further development on the clinical, scientific and economic fronts. The numerous changes, including paradigm shifts, in medicine, society, the health-care system and scientific innovations present new challenges to the specialty. This leads to questions about priority, problem areas and weaknesses as well as to new opportunities for the field and the overall question if it will be possible to meet the paradigm shifts and problems by the creation of new structures. In the light of the need for and the potential of design measures, this article presents a SWOT analysis of the specialty's situation as a whole and in particular for gynaecology in German universities. One sees additional demands that add up to an expansion of the tasks. At the same time the shortage of new recruits becomes apparent. A broadening of the perspectives on women's health and individualised medicine come into focus. Partial solutions include new supporting structures, capacity measurements as well as even structural options. In particular, the department structure, that is common abroad, opens an opportunity for specialisation while maintaining unity for a broader further training and strengthened research. Chances and strengths of the specialty are especially effective in coordinated and concerted activities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275314 | PMC |
http://dx.doi.org/10.1055/s-0034-1383383 | DOI Listing |
Drug Discov Today
December 2024
Boston Consulting Group, 80 Charlotte Street, London, W1T 4DF, UK. Electronic address:
The past decades have seen breakthroughs in drug discovery that have revolutionized the treatment of many diseases. These paradigm-shifting treatments are often novel targeted therapies, directed at new areas of biology. To better understand these paradigm shifts, we conducted an analysis of the adoption of 25 drug classes from five major therapeutic areas (TAs).
View Article and Find Full Text PDFVision Res
December 2024
CAS Key Laboratory of Behavioral Science, Institute of Psychology, Chinese Academy of Sciences, Beijing 100101, China; Department of Psychology, University of Chinese Academy of Sciences, Beijing 100049, China; State Key Laboratory of Brain and Cognitive Science, Beijing 100101, China.
Visual adaptation to thin or large bodies was found to shift the subjective body normality towards the adapting body shape. Here we investigated the persistency of such adaptation effect by tracking the timecourse of decay of short-term body size adaptation in young healthy Chinese women. Participants adapted to contracted or expanded body images of unfamiliar female volunteers with a top-up paradigm.
View Article and Find Full Text PDFStud Hist Philos Sci
December 2024
Freudental Institute, Department of Mathematics, Faculty of Science, Utrecht University, The Netherlands. Electronic address:
This paper is a critical analysis of the structure of the quantum revolution. I consider the factual question of how, historically and theoretically, the classical gave way to the quantum, and I argue for an answer that shows, contra Thomas Kuhn's influential philosophy of science, that it is the logic, and not the sociology and psychology, of research that correctly explains the classical-to-the-quantum paradigm shift. My approach is based not on archival studies but on a careful reading, in their original historical context, of Max Planck's and Albert Einstein's well-known papers; the burden of my argument, which at points will be outspoken, consists, then, in identifying and removing the impediments that prevent us from reading these papers in themselves.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
December 2024
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY.
In the past decade, the treatment paradigm for chronic lymphocytic leukemia (CLL) has markedly shifted from traditional chemoimmunotherapy towards targeted therapies. A fixed-duration, targeted regimen with venetoclax, a potent oral BCL-2 inhibitor, combined with obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody (Ven-Obi), has become the standard to beat for time-limited therapy in CLL. Ven-Obi allows for the rapid induction of remissions with high rates of undetectable minimal residual disease (uMRD) in patients across different treatment settings.
View Article and Find Full Text PDFLung Cancer
December 2024
Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA. Electronic address:
A major paradigm shift in the diagnosis, management, and survival outcomes of early and advanced non-small cell lung cancer has transpired over the past few decades in thoracic oncology with the incorporation of molecular testing, targeted therapy, immunotherapy, neoadjuvant, and adjuvant approaches. However, transformation in the management and survival outcomes of rare lung tumors is lacking. Given the scarcity of these tumor types, randomized trials are rarely performed, and treatment is extrapolated from case series, tumor-agnostic trials, or cancers with similar histology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!